Updates in the Adjuvant Treatment of Non-Small Cell Lung Cancer

Abstract

Over the past decade there has been significant advancement in the systemic therapy of non-small cell lung cancer, especially in the metastatic setting. More recently, medications which have been proven in advanced disease have been shown to provide benefit in the adjuvant setting as well. We review two recent trials which have studied the use of EGFR-targeted therapies and checkpoint inhibitor therapies in patients who have undergone surgical therapy for resectable disease.